CAR-T-Therapie

CAR-T therapy engineers T cells to attack cancer; focus on auto/allo and targets.The sector's total market cap is 1563.16 billion USD, with a 24h change of +1.34%. Among 7 constituents, 7 are up (100.00%) and 0 are down (0%). The top gainer is Gilead Sciences Inc (GILD), with a 24h increase of +1.76%.CAR-T steady; breadth mixed. Favor leaders; be selective.
Name
Letzter Preis
Änderung %
Letzter Preis / Änderung %
Chart
Price Range
Aktion
JNJ
JNJJohnson & Johnson
267,82$267,82
+1,67 %+$4,40
267,82
+1,67 %
$262,43$267,99
AMGN
AMGNAmgen Inc
378,34$378,34
+0,61 %+$2,30
378,34
+0,61 %
$375,59$381,60
PFE
PFEPfizer Inc.
24,79$24,79
+0,97 %+$0,24
24,79
+0,97 %
$24,55$24,83
GILD
GILDGilead Sciences Inc
131,60$131,60
+1,75 %+$2,27
131,60
+1,75 %
$129,33$132,51
NVS
NVSNovartis AG
156,62$156,62
+1,04 %+$1,62
156,62
+1,04 %
$154,89$157,59
INCY
INCYIncyte Genomics Inc
119,14$119,14
+1,24 %+$1,47
119,14
+1,24 %
$117,57$120,00
GSK
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)
52,06$52,06
+1,38 %+$0,71
52,06
+1,38 %
$51,21$52,47